Wrong questions, wrong answers? are we getting the drugs we need?

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 367-369

  Lipworth, W L ^a,b   Kerridge, I H ^b   Day, R O ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; DRUG; HORMONE ANALOG; MONOCLONAL ANTIBODY;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; PRIORITY JOURNAL; REVIEW;

DRUG DISCOVERY; DRUG INDUSTRY; DRUG TOXICITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84857223541     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.335     Document Type: Review

References (10)

1. Vandenbroucke, J.P. & Psaty, B.M. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300, 2417-2419 (2008).
2. Olver, I.N. & Haines, I. What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? Med. J. Aust. 190, 74-77 (2009).
3. Kaitin, K. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010).
4. Schulman, K. et al. A national survey of provisions in clinical trial agreements between medical schools and industry sponsors. N. Engl. J. Med. 347, 1335-1341 (2002). (Pubitemid 35215325)
5. Zerhouni, E.A. Translational and clinical science-time for a new vision. N. Engl. J. Med. 353, 1621-1623 (2005). (Pubitemid 41434645)
6. Thiers, F., Sinskey, A. & Berndt, E. Trends in the globalization of clinical trials. Nat. Rev. Drug Discov. 7, 13-14 (2008).
7. Glickman, S. et al. Ethical and scientific implications of the globalization of clinical research. N. Engl. J. Med. 360, 816-823 (2009).
8. McIlwain, C., Townsend, D. & Tew, K. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25, 1639-1648 (2006).
9. Woodcock, J. & Lesko, L. Pharmacogenetics-tailoring treatment for the outliers. N. Engl. J. Med. 360, 811-813 (2009).
10. Hede, K. Foundation drives research agenda for multiple myeloma. J. Natl. Cancer Inst. 98, 573 (2006).